Close Menu

Ambry

Ambry Genetics has launched four targeted sequencing-based cancer panels: CancerNext, BreastNext, ColoNext, and OvaNext.

By Monica Heger
As exome sequencing quickly becomes the method of choice for diagnosing rare conditions, a number of academic groups and companies have launched tests in recent months and are reporting their first successes.

This story has been updated to include additional comments from Ambry Genetics and Sigma-Aldrich.
By Justin Petrone

By Monica Heger
2011 will likely be recognized as the year that genome sequencing broke out of the research realm and moved into the clinic.

Ambry Genetics is now offering sequencing services on Illumina's MiSeq instrument. It offers both single- and paired-end sequencing with 50-base pair or 100-base pair reads, as well as indexing and barcoding.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – The British Columbia Cancer Agency Genome Science Center has joined the Illumina Genome Network, the San Diego-based firm said this week.

Agilent Technologies and Ambry Genetics have signed an agreement under which Ambry will use Agilent's SureSelect Target Enrichment System for exome sequencing services, the companies said last week.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Ambry Genetics will use Agilent Technologies' SureSelect Target Enrichment System for the exome sequencing services it provides for its customers, the firms announced today.

Pages

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.